CRNC vs. ARQT
CRNC (Cerence Inc.) and ARQT (Arcutis Biotherapeutics, Inc.) are both stocks. CRNC operates in Software - Application (Technology), while ARQT operates in Biotechnology (Healthcare). Over the past 5 years, CRNC returned -38.01%/yr vs 0.93%/yr for ARQT. At a 0.26 correlation, their price movements are largely independent.
Performance
CRNC vs. ARQT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRNC achieves a -2.06% return, which is significantly higher than ARQT's -4.48% return.
CRNC
- 1D
- 0.10%
- 1M
- -1.41%
- 6M
- -15.22%
- YTD
- -2.06%
- 1Y
- 12.22%
- 3Y*
- -28.36%
- 5Y*
- -38.01%
- 10Y*
- —
ARQT
- 1D
- -3.61%
- 1M
- 13.78%
- 6M
- -1.70%
- YTD
- -4.48%
- 1Y
- 84.81%
- 3Y*
- 43.95%
- 5Y*
- 0.93%
- 10Y*
- —
CRNC vs. ARQT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
CRNC Cerence Inc. | -2.06% | 36.18% | -60.07% | 6.10% | -75.82% | -23.73% | 355.07% |
ARQT Arcutis Biotherapeutics, Inc. | -4.48% | 108.47% | 331.27% | -78.18% | -28.64% | -26.27% | 22.04% |
Correlation
The correlation between CRNC and ARQT is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.20 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Jan 31, 2020 | 0.26 |
Fundamentals
CRNC:
$473.12M
ARQT:
$3.47B
CRNC:
-$0.44
ARQT:
-$0.02
CRNC:
1.56
ARQT:
8.85
CRNC:
3.10
ARQT:
18.92
CRNC:
$302.14M
ARQT:
$415.62M
CRNC:
$235.95M
ARQT:
$377.98M
CRNC:
$34.08M
ARQT:
$12.21M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRNC vs. ARQT — Risk / Return Rank
CRNC
ARQT
CRNC vs. ARQT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Cerence Inc. (CRNC) and Arcutis Biotherapeutics, Inc. (ARQT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRNC | ARQT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.34 | ||
| Sortino ratioReturn per unit of downside risk | -1.45 | ||
| Omega ratioGain probability vs. loss probability | 1.09 | 1.27 | -0.18 |
| Calmar ratioReturn relative to maximum drawdown | 0.13 | 2.19 | -2.06 |
| Martin ratioReturn relative to average drawdown | 0.26 | 4.91 | -4.64 |
Loading charts...
Drawdowns
CRNC vs. ARQT - Drawdown Comparison
The maximum CRNC drawdown since its inception was -98.22%, roughly equal to the maximum ARQT drawdown of -95.02%. Use the drawdown chart below to compare losses from any high point for CRNC and ARQT.
Loading charts...
Drawdown Indicators
| CRNC | ARQT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.22% | -95.02% | -3.20% |
Max Drawdown (1Y)Largest decline over 1 year | -55.92% | -37.50% | -18.42% |
Max Drawdown (3Y)Largest decline over 3 years | -91.48% | -83.24% | -8.24% |
Max Drawdown (5Y)Largest decline over 5 years | -98.02% | -93.17% | -4.85% |
Current DrawdownCurrent decline from peak | -92.15% | -24.99% | -67.16% |
Average DrawdownAverage peak-to-trough decline | -63.44% | -49.82% | -13.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.13% | 16.70% | +10.43% |
Volatility
CRNC vs. ARQT - Volatility Comparison
Cerence Inc. (CRNC) has a higher volatility of 20.25% compared to Arcutis Biotherapeutics, Inc. (ARQT) at 12.23%. This indicates that CRNC's price experiences larger fluctuations and is considered to be riskier than ARQT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CRNC | ARQT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 20.25% | 12.23% | +8.02% |
Volatility (6M)Calculated over the trailing 6-month period | 59.52% | 37.76% | +21.76% |
Volatility (1Y)Calculated over the trailing 1-year period | 85.62% | 58.13% | +27.49% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 113.80% | 71.85% | +41.95% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 106.16% | 76.61% | +29.55% |
Dividends
CRNC vs. ARQT - Dividend Comparison
Neither CRNC nor ARQT has paid dividends to shareholders.
Financials
CRNC vs. ARQT - Financials Comparison
This section allows you to compare key financial metrics between Cerence Inc. and Arcutis Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CRNC vs. ARQT - Profitability Comparison
CRNC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Cerence Inc. reported a gross profit of 47.30M and revenue of 64.19M. Therefore, the gross margin over that period was 73.7%.
ARQT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Arcutis Biotherapeutics, Inc. reported a gross profit of 95.61M and revenue of 105.40M. Therefore, the gross margin over that period was 90.7%.
CRNC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Cerence Inc. reported an operating income of -2.44M and revenue of 64.19M, resulting in an operating margin of -3.8%.
ARQT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Arcutis Biotherapeutics, Inc. reported an operating income of -9.09M and revenue of 105.40M, resulting in an operating margin of -8.6%.
CRNC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Cerence Inc. reported a net income of 1.67M and revenue of 64.19M, resulting in a net margin of 2.6%.
ARQT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Arcutis Biotherapeutics, Inc. reported a net income of -11.30M and revenue of 105.40M, resulting in a net margin of -10.7%.
Frequently Asked Questions
CRNC and ARQT have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRNC has higher volatility (20.25%) compared to ARQT (12.23%). In terms of maximum drawdown, CRNC dropped -98.22% vs ARQT's -95.02%.
ARQT currently has the higher Sharpe Ratio (1.42 vs 0.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CRNC and ARQT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer